规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售

产品描述

来源:
Rabbit
应用:
WB 1:500-1:3000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse, Rat
克隆:
Polyclonal
特异性:
FGFR3 Antibody detects endogenous levels of total FGFR3.
RRID:
AB_2833341
引用格式: Affinity Biosciences Cat# AF0160, RRID:AB_2833341.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

ACH; CD 333; CD333; CD333 antigen; CEK 2; CEK2; FGFR 3; FGFR-3; FGFR3; FGFR3_HUMAN; Fibroblast growth factor receptor 3 (achondroplasia thanatophoric dwarfism); Fibroblast growth factor receptor 3; Heparin binding growth factor receptor; HSFGFR3EX; Hydroxyaryl protein kinase; JTK 4; JTK4; MFR 3; SAM 3; Tyrosine kinase JTK 4; Tyrosine kinase JTK4; Z FGFR 3;

抗原和靶标

免疫原:

A synthesized peptide derived from human FGFR3, corresponding to a region within C-terminal amino acids.

基因/基因ID:
描述:
FGFR3 a receptor tyrosine kinase of the highly-conserved FGFR family that binds fibroblast growth factor (FGF). Mutations are associated with thanatophoric dysplasia (TD), craniosynostosis Adelaide type, many craniosynostotic syndromes and bone malformations. Three splice-variant isoforms have been described. Activating point mutations cause dwarfism, including achondroplasia, hypochrondroplasia and thanatophoric dysplasia, and facial and other morphogenetic disorders, including Crouzon syndrome, craniosynostosis Adelaide type, San Diego skeletal displasia and Muenke syndrome. Translocations t(4;14) involving the IgH region are common in multiple myeloma and frequently involve FGFR3.

研究领域

· Cellular Processes > Transport and catabolism > Endocytosis.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Signaling pathways regulating pluripotency of stem cells.   (View pathway)

· Cellular Processes > Cell motility > Regulation of actin cytoskeleton.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Bladder cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer.   (View pathway)

文献引用

1). Dual role of FOXG1 in regulating gliogenesis in the developing neocortex via the FGF signalling pathway. eLife, 2025 (PubMed: 40085500) [IF=6.4]

Application: IF/ICC    Species: Mouse    Sample:

Figure 3 FOXG1 binds and regulates the expression of Fgfr3. (A) RNA-seq analysis of FACS-purified Control and Foxg1 loss-of-function (LOF) progenitors harvested two days after labelling at E15.5. Gliogenic factors such as Nfia, Id3, and Olig3 are upregulated, and neuronal markers such as Pou3f1 and Robo4 are downregulated. (B–D) Multimodal analysis comparing FOXG1 occupancy (ChIP-seq) and bivalent epigenetic marks (H3K4Me3 and H3K27Me3) and astrocyte-enriched genes from Telley et al., 2019 reveals a list of 19 genes common to each dataset (B). Four of these are upregulated upon loss of Foxg1, including the known gliogenic gene Fgfr3 (D). FOXG1 occupies a –26 kb enhancer region of Fgfr3 (C). (E) KEGG analysis of the upregulated genes from (A) identifies the MAPK signalling pathway downstream of FGF signalling. (F) Loss of Foxg1 from E15.5 progenitors (hGFAP-CreERT2, tamoxifen at E15.5) causes upregulation of FGFR3 receptor by E17.5 as seen in cells near the VZ of the somatosensory cortex. Boxes (F) indicate the regions in high magnification shown in the adjacent panels (G). Dashed circles outline the regions of interest (ROIs) identified in the DAPI channel used for intensity quantification in (H). (G; n = 50 [Control and Foxg1 LOF] ROIs from N = 3 brains) and phosphorylated-ERK1/2 (H; n = 67 [Control] and 89 [Foxg1 LOF]) cells from N = 3 brains (biologically independent replicates). Statistical test: Mann–Whitney test *p

2). Deficiency of EXT1 and FGFR3 genes promotes chondrocyte differentiation, leading to the induction of osteochondroma formation. Bone, 2025 (PubMed: 39675407) [IF=3.5]

3). The Effect of Wnt Family Member 5a Gene Silencing on the Proliferation of Achondroplasia Using a DNAzymes-CoOOH Nanocomposite. Journal of Biomedical Nanotechnology, 2022 (PubMed: 34446145) [IF=2.9]

4). Liraglutide regulates lipid metabolism via FGF21-LKB1-AMPK-ACC1 pathway in white adipose tissues and macrophage of type 2 diabetic mice. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2021 (PubMed: 33640604) [IF=2.5]

Application: WB    Species: mice    Sample: RAW264.7 cells

Fig. 3. Effects of LRG on the gene expression in PA-treated LPS-induced RAW264.7 cells. (A) Effects of LRG on secretion of FGF21 in culture supernatant; (B) Effects of LRG on mRNA expression of FGF21; (C) Effects of LRG on mRNA expression of ACC1; (D) Effects of LRG on the protein expression of FGF21, p-FGFR2 and p-FGFR3; (E) Quantification of Fig. 3D; (F) Effect of LRG on protein expression of AMPK pathway; (G) Quantification of Fig. 3F. #p < 0.05, ##p < 0.01 vs CON; $p < 0.05, $$p < 0.01 vs LPS þ HGHP; &p < 0.05, &&p < 0.01 vs PA þ LPS þ LRG (L); *p < 0.05, **p < 0.01 vs PA þ LPS þ LRG (M).

限制条款

产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)

产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.